Liraglutide vs NAD+
Saxenda, Victoza
Liraglutide and NAD+ are both metabolic compounds evaluated on Vial: Liraglutide is FDA approved with clinical-trial evidence, and NAD+ is legally compoundable with clinical-trial evidence, offered by 14 and 18 verified providers respectively.
Vial summary · compiled from public records
At a glance
Liraglutide
Sold as Saxenda, Victoza
- Category
- Metabolic
- FDA / legal status
- FDA Approved
- Route
- Subcutaneous
NAD+
- Category
- Metabolic
- FDA / legal status
- Legally Compoundable
- Route
- Intravenous, subcutaneous
Side by side
| Field | Liraglutide | NAD+ |
|---|---|---|
| Category | Metabolic | Metabolic |
| Brand names | Saxenda, Victoza | — |
| FDA / legal status | FDA Approved | Legally Compoundable |
| Evidence tier | Clinical Trials | Clinical Trials |
| Administration route | Subcutaneous | Intravenous, subcutaneous |
| Compounding access | FDA-approved product, dispensed by prescription | Legally Compoundable |
| Providers on Vial | 14 listed | 18 listed |
| Typical price band | $$ | $ to $$$ |
Verified providers offering each
Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
About each compound
About Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first GLP-1 agents to demonstrate meaningful weight loss in clinical trials, producing 5–8% body weight reduction on average. Though largely superseded by weekly agents, it remains a clinically validated option. Compounded liraglutide is available through select pharmacies.
About NAD+
A coenzyme present in all living cells, nicotinamide adenine dinucleotide (NAD+) functions as a critical electron carrier in cellular metabolism and serves as a substrate for enzymes involved in DNA repair, cellular signaling, and epigenetic regulation. Cellular NAD+ levels decline with age, which has been associated with metabolic dysfunction and age-related pathologies. Research focuses on NAD+ precursor supplementation (such as nicotinamide riboside and nicotinamide mononucleotide) to investigate potential therapeutic applications in metabolic disorders, neurodegeneration, and aging-related conditions.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.